These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11888074)

  • 1. The advent of targeted therapeutics and implications for pathologists.
    Hess JL
    Am J Clin Pathol; 2002 Mar; 117(3):355-7. PubMed ID: 11888074
    [No Abstract]   [Full Text] [Related]  

  • 2. New hope for cancer.
    Lemonick MD; Park A
    Time; 2001 May; 157(21):62-9. PubMed ID: 11393038
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted therapeutics and implications for pathologists.
    Geyer SJ; Johnson PC
    Am J Clin Pathol; 2002 Jul; 118(1):144; author reply 144. PubMed ID: 12109849
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating cancer's kinase 'addiction'.
    Baselga J; Arribas J
    Nat Med; 2004 Aug; 10(8):786-7. PubMed ID: 15286778
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
    Joensuu H
    Duodecim; 2002; 118(22):2305-12. PubMed ID: 12523107
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on the use of imatinib mesylate.
    Sawyers CL
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tyrosine kinase inhibitor STI571--a breakthrough in leukemia treatment?].
    Czechowska A; Błasiak J
    Postepy Biochem; 2003; 49(3):157-67. PubMed ID: 15083608
    [No Abstract]   [Full Text] [Related]  

  • 9. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib: the promise of a "magic bullet" for cancer fulfilled.
    Henderson CA
    J Med Assoc Ga; 2003; 92(1):12-4, 22. PubMed ID: 12743899
    [No Abstract]   [Full Text] [Related]  

  • 11. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
    Rukavitsyn OA; Pop VP
    Ter Arkh; 2008; 80(7):80-4. PubMed ID: 18763606
    [No Abstract]   [Full Text] [Related]  

  • 12. [Imatinib--en epoch-making new drug against chronic myeloid leukemia].
    Lakartidningen; 2003 Jun; 100(26-27):2283. PubMed ID: 12872372
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials referral resource. Current clinical trials of imatinib mesylate.
    Murgo AJ; Wood KF; Schoenfeldt M; Smith MA; Saxman S
    Oncology (Williston Park); 2003 Apr; 17(4):513, 518, 521 passim. PubMed ID: 12735145
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction: chronic myelogenous leukemia (CML).
    Jabbour E; Kantarjian H
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S1-3. PubMed ID: 17292735
    [No Abstract]   [Full Text] [Related]  

  • 17. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ
    Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract]   [Full Text] [Related]  

  • 19. [c-kit: an irresistible ascension from diagnostic marker to therapeutic].
    Scoazec JY
    Ann Pathol; 2002 Jun; 22(3):173-5. PubMed ID: 12410099
    [No Abstract]   [Full Text] [Related]  

  • 20. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
    Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
    Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.